Possible side effects and serious risks: GLP-1 medications commonly cause nausea and other gastrointestinal effects
Individuals with prior use of oral antidiabetic drugs or GLP-1 receptor agonists, a history of bariatric surgery, or conditions associated with unintentional weight loss (including malignancy or chronic infection) were excluded
The standard starting dose is 0.25 mg injected subcutaneously once per week
Combining them, they form even greater protection against oxidative damage
The actual time of day is less critical than the day itself, but most patients find success injecting in the morning or early evening
In-person care Baltimore Clinic Visits In-person appointments can support examination, vital signs, body measurements, injection education, and services that cannot be completed virtually